Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes

B. Oran*, K.W. Ahn, C. Fretham, A. Beitinjaneh, A. Bashey, A. Pawarode, B. Wirk, B.L. Scott, B.N. Savani, C. Bredeson, D. Weisdorf, D.I. Marks, D. Rizzieri, E. Copelan, G.C. Hildebrandt, G.A. Hale, H.S. Murthy, H.M. Lazarus, J. Cerny, J.L. LiesveldJ.A. Yared, J. Yves-Cahn, J. Szer, L.F. Verdonck, MahmoudAljurf MahmoudAljurf, M. van der Poel, M. Litzow, M. Kalaycio, M.R. Grunwald, M. AngelDiaz, M. Sabloff, M.A. Kharfan-Dabaja, N.S. Majhail, N. Farhadfar, R. Reshef, R.F. Olsson, R.P. Gale, R. Nakamura, S. Seo, S. Chhabra, S. Hashmi, S. Farhan, S. Ganguly, S. Nathan, TaigaNishihori TaigaNishihori, T. Jain, VaibhavAgrawal VaibhavAgrawal, U. Bacher, U. Popat, W. Saber

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Number of pages10
JournalTransplantation and Cellular Therapy
Volume27
Issue number11
DOIs
Publication statusPublished - 1 Nov 2021

Keywords

  • MDS
  • Transplantation
  • Survival
  • Relapse
  • Melphalan
  • STEM-CELL TRANSPLANTATION
  • VERSUS-HOST-DISEASE
  • ACUTE MYELOID-LEUKEMIA
  • ALLOGENEIC TRANSPLANTATION
  • CONDITIONING REGIMENS
  • SURVIVAL
  • RELAPSE
  • MALIGNANCIES
  • CYTOGENETICS
  • MUTATIONS

Cite this